XML 28 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue Recognition and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Recognition and Concentration of Credit Risk Revenue Recognition and Concentration of Credit Risk
During the years ended December 31, 2024 and 2023, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:

Customer2024 Revenue% of Total
Revenue		2023 Revenue% of Total
Revenue
ApolloBio Corporation$217,756 100 %$245,056 29 %
All other, including affiliated entity— — 586,954 71 
Total revenue$217,756 100 %$832,010 100 %

No revenue recognized during the years ended December 31, 2024 and 2023 was in deferred revenue as of December 31, 2023 and 2022, respectively.
As of December 31, 2024 and 2023, the Company had no accounts receivable balance.